Lördag 21 November | 04:37:39 Europe / Stockholm
Est. tid*
2027-08-19 08:30 Kvartalsrapport 2027-Q2
2027-04-29 08:30 Kvartalsrapport 2027-Q1
2027-02-18 08:30 Bokslutskommuniké 2026
2026-11-05 - Kvartalsrapport 2026-Q3
2026-08-20 - Kvartalsrapport 2026-Q2
2026-07-20 - Extra Bolagsstämma 2026
2026-05-08 - X-dag ordinarie utdelning MVIR 0.00 SEK
2026-05-07 - Årsstämma
2026-05-05 - Kvartalsrapport 2026-Q1
2026-02-18 - Bokslutskommuniké 2025
2025-11-06 - Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-08 - X-dag ordinarie utdelning MVIR 0.00 SEK
2025-05-07 - Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-18 - Bokslutskommuniké 2024
2024-11-06 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning MVIR 0.00 SEK
2024-05-07 - Årsstämma
2024-04-30 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-12-01 - Extra Bolagsstämma 2024
2023-10-27 - Kvartalsrapport 2023-Q3
2023-08-18 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning MVIR 0.00 SEK
2023-05-24 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-19 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning MVIR 0.00 SEK
2022-05-05 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-15 - Bokslutskommuniké 2021
2021-11-03 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning MVIR 0.00 SEK
2021-05-05 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-03-11 - Extra Bolagsstämma 2021
2021-02-26 - Bokslutskommuniké 2020
2021-01-13 - Extra Bolagsstämma 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-06 - X-dag ordinarie utdelning MVIR 0.00 SEK
2020-05-05 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-27 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-10 - X-dag ordinarie utdelning MVIR 0.00 SEK
2019-05-09 - Årsstämma
2019-05-03 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-07-25 - Kvartalsrapport 2018-Q2
2018-05-04 - X-dag ordinarie utdelning MVIR 0.00 SEK
2018-05-03 - Årsstämma
2018-04-27 - Kvartalsrapport 2018-Q1
2018-02-14 - Bokslutskommuniké 2017
2017-10-26 - Kvartalsrapport 2017-Q3
2017-07-25 - Kvartalsrapport 2017-Q2
2017-05-04 - X-dag ordinarie utdelning MVIR 0.00 SEK
2017-05-03 - Årsstämma
2017-04-28 - Kvartalsrapport 2017-Q1
2017-03-08 - Kapitalmarknadsdag 2017
2017-02-17 - Bokslutskommuniké 2016
2017-02-02 - Extra Bolagsstämma 2017
2016-11-10 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-04 - X-dag ordinarie utdelning MVIR 0.00 SEK
2016-05-03 - Årsstämma
2016-04-28 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-11-20 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2
2015-05-06 - X-dag ordinarie utdelning MVIR 0.00 SEK
2015-05-05 - Årsstämma
2015-05-05 - Kvartalsrapport 2015-Q1
2015-02-27 - Bokslutskommuniké 2014
2014-11-20 - Extra Bolagsstämma 2014
2014-11-20 - Kvartalsrapport 2014-Q3
2014-10-16 - Kapitalmarknadsdag 2014
2014-08-21 - Analytiker möte 2014
2014-08-21 - Kvartalsrapport 2014-Q2
2014-05-09 - X-dag ordinarie utdelning MVIR 0.00 SEK
2014-05-08 - Årsstämma
2014-05-08 - Kvartalsrapport 2014-Q1
2014-02-24 - Bokslutskommuniké 2013
2013-11-21 - Kvartalsrapport 2013-Q3
2013-10-10 - Kapitalmarknadsdag 2013
2013-08-22 - Kvartalsrapport 2013-Q2
2013-05-07 - X-dag ordinarie utdelning MVIR 0.00 SEK
2013-05-06 - Årsstämma
2013-05-06 - Kvartalsrapport 2013-Q1
2013-03-13 - 15-7 2013
2013-02-22 - Bokslutskommuniké 2012
2012-11-20 - Kvartalsrapport 2012-Q3
2012-11-19 - Kvartalsrapport 2012-Q3
2012-08-23 - Kvartalsrapport 2012-Q2
2012-05-11 - X-dag ordinarie utdelning MVIR 0.00 SEK
2012-05-10 - Årsstämma
2012-05-10 - Kvartalsrapport 2012-Q1
2012-02-22 - Bokslutskommuniké 2011
2011-11-15 - Kapitalmarknadsdag 2011
2011-10-24 - Kvartalsrapport 2011-Q3
2011-07-08 - Kvartalsrapport 2011-Q2
2011-05-06 - X-dag ordinarie utdelning MVIR 0.00 SEK
2011-05-05 - Årsstämma
2011-05-05 - Extra Bolagsstämma 2011
2011-05-05 - Kvartalsrapport 2011-Q1
2011-02-22 - Bokslutskommuniké 2010
2010-10-22 - Kvartalsrapport 2010-Q3
2010-07-08 - Kvartalsrapport 2010-Q2
2010-04-30 - X-dag ordinarie utdelning MVIR 0.00 SEK
2010-04-29 - Kvartalsrapport 2010-Q1
2010-02-18 - Bokslutskommuniké 2009
2009-10-21 - Kvartalsrapport 2009-Q3
2009-07-09 - Kvartalsrapport 2009-Q2
2009-04-24 - X-dag ordinarie utdelning MVIR 0.00 SEK
2009-04-23 - Årsstämma
2009-04-23 - Kvartalsrapport 2009-Q1
LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Medivir utvecklar läkemedel med fokus på cancersjukdomar där de medicinska behoven är stora. Läkemedelskandidaterna riktas mot indikationsområden där tillgängliga behandlingsmetoder är begränsade eller saknas. Medivir fokuserar på utvecklingen av fostrox, en läkemedelskandidat som har utformats för att selektivt behandla cancerceller i levern. Bolaget grundades år 1988 och har huvudkontor i Huddinge.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

FDA grants Medivir’s MIV-711 Rare Pediatric Disease Designation for Osteogenesis Imperfecta

2026-11-19 09:00:00

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments in areas of high unmet medical need, announced today that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to its selective cathepsin K inhibitor MIV-711 for the treatment of Osteogenesis Imperfecta (OI). MIV-711 already holds Orphan Drug Designation (ODD) in OI, as well as ODD and RPDD in Perthes disease. The decision strengthens MIV-711 ahead of the planned proof-of-concept study in OI and, upon a future approval, MIV-711 may also qualify for a Priority Review Voucher – a transferable asset that has sold for USD 180–210 million per voucher in 2026.

MIV-711 targets the underlying bone fragility
MIV-711 inhibits cathepsin K, the main enzyme used by osteoclasts to degrade collagen in bone tissue. By reducing excessive bone resorption, MIV-711 aims to restore the balance between bone resorption and bone formation, thereby preventing fractures and skeletal deformities.

For RPDD, the FDA requires a scientific rationale and supportive data suggesting that the drug may be effective in the disease. In an OI-specific animal model, MIV-711 has shown significant and dose-dependent improvements in bone strength, bone quality and bone morphology, and clinical data in osteoarthritis support MIV-711’s ability to counteract bone degradation in humans. In its decision, the FDA concluded that OI meets the criteria for a rare pediatric disease, citing, among other things, high bone fragility with susceptibility to fracture, skeletal deformities, respiratory complications, pain and short stature.

There is currently no approved treatment that addresses the underlying bone fragility in Osteogenesis Imperfecta, and Medivir estimates the market potential for such a treatment at a minimum of USD 2.5 billion.

Priority Review Voucher – a potentially valuable asset
With RPDD, the FDA may grant Medivir a Priority Review Voucher (PRV) upon marketing approval of MIV-711 in OI. The voucher provides priority review of a subsequent marketing application and can be sold on to other companies. Transactions completed in 2026 have been concluded at between USD 180 million and USD 210 million per voucher. The PRV program has been extended several times since its introduction in 2012, most recently in February 2026, and currently runs until September 30, 2029.

  • “The FDA’s decision to grant RPDD in Osteogenesis Imperfecta confirms both the significant unmet medical need and the scientific rationale for MIV-711. Children with OI live with recurrent fractures, skeletal deformities and chronic pain, and there is still no approved treatment that addresses the underlying bone fragility. We believe MIV-711 has the potential to become the first. With Orphan Drug Designation and RPDD in both OI and Perthes disease, a finalized study design and secured funding, MIV-711 is well positioned for the next phase of development. Our focus now is on initiating the proof-of-concept study and demonstrating what MIV-711 can mean for patients,” says Jens Lindberg, CEO, Medivir.

For additional information, please contact:
Jens Lindberg, CEO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: jens.lindberg@medivir.com